Sign in
4

Changes in Ownership

Actinium Pharmaceuticals, Inc. Filed Acc 0001213900-17-002501

Options or other derivatives

  • CEO and Interim CFO acquired 250,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

DAVE KAUSHIK J · CEO and Interim CFO

Table II: Derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2017-03-14 Grant or award : show line 1 in the form Options to purchase common stock +250,000 $1.39 $347,500 250,000 D
Loading xslF345X03/f4031417dave_actinium.xml…